Bausch Is Adding to Glenview’s Woes

Larry Robbins mixes up the hedge fund’s health-care holdings — but can’t stop the bleeding.

Larry Robbins, CEO of Glenview Capital Management. (Kholood Eid/Bloomberg)

Larry Robbins, CEO of Glenview Capital Management.

(Kholood Eid/Bloomberg)

Bausch Health Cos., that Canadian company formerly known as Valeant Pharmaceuticals International that is still struggling with heavy debt, is now one of the biggest positions of Larry Robbins’s Glenview Capital Management, according to recent securities filings.

But Bausch, a shadow of its former self, seems to be causing grief to hedge funds who believe in it.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related